Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
- Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesis
- Refined focus on neurodegenerative disease targets
- Proceeds to be used to advance lead programme targeting FAN1 nuclease in Huntington’s Disease towards the clinic